Zarxio Coverage On Par With Innovators Even Without Interchangeable Designation
Executive Summary
Avalere survey suggests payers are comfortable with covering the biosimilar but not necessarily actively promoting it over Neupogen or other competing brands.
You may also be interested in...
A Look At Payers' Early Game Plans For Driving Biosimilar Use
Interviews with US payers suggest that at first they are more likely to focus on promoting biosimilars in treatment-naïve patients, as opposed to switching those on branded drugs, according to a new Datamonitor report.
Medicaid ‘Price Verification’ Audit Proposal Aims To Promote Cell, Gene Therapy Rebate Concessions
CMS proposed rule impact may be ‘modest’ but is framed as ensuring patient access to cutting edge treatments by helping to control Medicaid spending. Biden administration initiative also aims to address misclassification of brand drugs, duplicative 340B discounts, and PBM spread pricing.
Medicare Unlikely To Embrace Cost Effectiveness In Early Price Negotiations – ICER’s Pearson
The government’s rush to stand up the negotiation program by the fall likely means an approach to cost effectiveness will be left out of at least the first cycle. But it could be incorporated over time.